Advances in High Sensitivity Protein Detection from Biofluids and the Potential in Early Diagnosis and Therapeutic Monitoring

Featuring:

Yuehan Feng, PhD

Sr. Director, Application Sciences, 
Biognosys

Xiao-Jun Ma, PhD
Chief Technology Officer, 
Alamar Biosciences

Alex Forrest-Hay
VP of Sales, 
Alamar Biosciences

VIEW ON DEMAND

Circulating proteins found in biofluids represent ideal biomarkers for early disease detection and can be collected non-invasively. Detection from biofluids, however, is challenging as highly abundant proteins mask the detection of low abundance proteins involved in the regulation of key biochemical cascades. The NULISA™ Platform improves the sensitivity of traditional immunoassays and provides highly multiplexed quantification of both low- and high-abundance proteins from the same 10uL sample. The NULISAseq™ Inflammation Panel 250 provides deep coverage of cytokines and markers of immune response enabling the discovery of signatures of disease progression, disease heterogeneity, or to predict the development of serious reactions.

VIEW ON DEMAND
Linkedin

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Linkedin

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.